Future Research Directions To further clarify remaining uncertainty, future research should prioritize: Longer follow-up periods in large, active-comparator cohorts Mandatory histologic subtype linkage in registry studies International collaboration to increase power for rare outcomes like MTC Prospective registries in high-risk populations Transparent reporting of surveillance intensity and imaging utilization Final Conclusions After comprehensive review of mechanistic data, randomized trials, observational cohorts, pharmacovigilance analyses, and expert syntheses, the following conclusions are supported: There is no convincing human evidence that GLP-1 receptor agonists cause papillary, follicular, or Oncocytic (Hrthle cell) thyroid cancers The FDA boxed warning is appropriately narrow, reflecting rodent findings relevant to medullary thyroid carcinoma and MEN2 Apparent associations in some studies are plausibly explained by detection bias, confounding, and outcome misclassification Broad extrapolation of the warning to all thyroid cancers is not scientifically justified Evidence-based, subtype-specific counseling is essential to avoid unnecessary fear and ensure appropriate use of effective therapies This white paper is intended to serve as a durable reference for clinicians, patients, media professionals, and policymakers navigating a complex topic at the intersection of endocrinology, oncology, and public communication
Microglia are inherent immune effector cells in the central nervous system, which play an essential role in regulating neuronal development, neuron apoptosis, and other physiological processes (62)
doi:10.1016/S0167-4781(00)00067-1 3
Whats Inside a Biocare Shake Every ingredient earns its place
Thnh phn: Reduced Glutathione 500 mg , Cellulose, magnesium stearate and silicon dioxide
Clinical Update 1/13/2023 How Much Phytate in Pea Protein
